Shares of Altimmune, Inc. (NASDAQ:ALT – Get Free Report) have received an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have assigned a buy recommendation to the company. [...]
Altimmune, Inc. (NASDAQ:ALT) Receives $15.71 Consensus PT from Analysts
